Factors predictive of late remission in a cohort of Chinese patients with newly diagnosed epilepsy

Abstract

Patients with a high frequency of seizures prior to treatment or multiple seizure types may achieve late remission. Particular consideration should be given to these patients.

Treatment response and its predictors among epilepsy patients: a retrospective cohort study

“…In contrast to our findings, previous studies reported a lower proportion of patients with no remission ranging from 15-30.9%. [7,11,15,18]. In general, despite the differences in the definition of the patterns, the current study found lower total remission (early and late) and a higher percentage of patients with no remission.…”

“…In a study conducted by Zhang et al in China, 80% seizure remission was observed [18]. Similarly, a slightly higher remission rate (69.1%) was reported by Shen et al [7]. On the other hand, seizure remission was reported as low as in 43.6% of patients in a study by Rizaldy et al [19].…”

“…In the current study based on patterns of response, 46 % of the patients entered early remission, around one-fifth entered late remission, two out of three had remission followed by relapse and more than one-third never entered remission. In a study by Shen et al early remission was achieved in 51.6%, and late remission was subsequently achieved in 17.5% of patients [7]. Another study in Italy reported that 56.2% entered 2-year early remission [20].…”

“…Antiepileptic drugs (AEDs) are the mainstay of treatment, and about 70% of patients with newly diagnosed epilepsy achieve remission [6,7]. The patient's response requires a careful diagnosis of seizure types, knowledge of pharmacotherapy and patient compliance to treatment [8].…”

Seizures and risk of epilepsy in anti‐NMDAR, anti‐LGI1, and anti‐GABABR encephalitis

“…21,22 Previous literature on epilepsy have also suggested IEDs may predict unfavorable seizure outcomes and refractory epilepsy. 23,24 As for immunotherapy delay, one of the main causes was atypical and insidious symptoms, for example, symptomatic seizures occurred as the unique presentation in several patients with AIE, particularly in anti-LGI1 encephalitis. To date, there were fewer studies reporting the relationship between immunotherapy delay and the development of epilepsy in neuronal surface antibody-mediated autoimmune encephalitis.…”